# Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

> **NCT06649864** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 20 (estimated)

## Conditions studied

- Liver Transplant; Complications
- Liver Diseases

## Interventions

- **DRUG:** Autologous adipose derived mesenchymal stromal cells (AMSC)

## Key facts

- **NCT ID:** NCT06649864
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02
- **Primary completion:** 2028-01
- **Final completion:** 2028-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649864, "Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06649864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*